On Tuesday, Genmab ADR (NASDAQ: GMAB) opened lower -3.16% from the last session, before settling in for the closing price of $31.94. Price fluctuations for GMAB have ranged from $17.24 to $33.65 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 28.01%. Company’s average yearly earnings per share was noted 7.71% at the time writing. With a float of $615.99 million, this company’s outstanding shares have now reached $615.99 million.
Considering the fact that the conglomerate employs 2682 people, you should pay attention to its efficiency factor.
Genmab ADR (GMAB) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Genmab ADR is 0.00%, while institutional ownership is 10.31%. The most recent insider transaction that took place on Jun 17 ’25, was worth 67,200.
Genmab ADR (GMAB) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 0.84 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.28) by 0.56. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.94% during the next five years compared to 28.01% growth over the previous five years of trading.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
Check out the current performance indicators for Genmab ADR (GMAB). In the past quarter, the stock posted a quick ratio of 6.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.31. Likewise, its price to free cash flow for the trailing twelve months is 15.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.35, a number that is poised to hit 0.43 in the next quarter and is forecasted to reach 1.58 in one year’s time.
Technical Analysis of Genmab ADR (GMAB)
Compared to the last year’s volume of 1.62 million, its volume of 1.12 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 67.21%.
During the past 100 days, Genmab ADR’s (GMAB) raw stochastic average was set at 78.51%, which indicates a significant increase from 38.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was higher than the 0.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.87, while its 200-day Moving Average is $24.38. Nevertheless, the first resistance level for the watch stands at $31.36 in the near term. At $31.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $32.01. If the price goes on to break the first support level at $30.71, it is likely to go to the next support level at $30.50. Now, if the price goes above the second support level, the third support stands at $30.06.
Genmab ADR (NASDAQ: GMAB) Key Stats
There are currently 642,384K shares outstanding in the company with a market cap of 19.05 billion. Presently, the company’s annual sales total 3,121 M according to its annual income of 1,137 M. Last quarter, the company’s sales amounted to 1,022 M and its income totaled 401,000 K.
